Rodolfo Nunes Campos

Publications (2)5.64 Total impact

• Article: Treatment-resistant depression increases health costs and resource utilization.

  Beatrice Alinka Lepine, Ricardo Alberto Moreno, Rodolfo Nunes Campos, Bernard François Couttolenc
  [show abstract] [hide abstract]
  ABSTRACT: Major Depressive Disorder (MDD) is a debilitating condition with a marked social impact. The impact of MDD and Treatment-Resistant Depression (TRD+) within the Brazilian health system is largely unknown. The goal of this study was to compare resource utilization and costs of care for treatment-resistant MDD relative to non-treatment-resistant depression (TRD-). We retrospectively analyzed the records of 212 patients who had been diagnosed with MDD according to the ICD-10 criteria. Specific criteria were used to identify patients with TRD+. Resource utilization was estimated, and the consumption of medication was annualized. We obtained information on medical visits, procedures, hospitalizations, emergency department visits and medication use related or not to MDD. The sample consisted of 90 TRD+ and 122 TRD- patients. TRD+ patients used significantly more resources from the psychiatric service, but not from non-psychiatric clinics, compared to TRD- patients. Furthermore, TRD+ patients were significantly more likely to require hospitalizations. Overall, TRD+ patients imposed significantly higher (81.5%) annual costs compared to TRD- patients (R$ 5,520.85; US$ 3,075.34 vs. R$ 3,042.14; US$ 1,694.60). These findings demonstrate the burden of MDD, and especially of TRD+ patients, to the tertiary public health system. Our study should raise awareness of the impact of TRD+ and should be considered by policy makers when implementing public mental health initiatives.
  Revista Brasileira de Psiquiatria 12/2012; 34(4):379-88. · 1.20 Impact Factor
• Source

  Available from: Doris Hupfeld Moreno

  Article: SHORT COMMUNICATION: Apolipoprotein E genotype and cognition in bipolar disorder.

  Márcio Gerhardt Soeira-de-Souza, Márcio Gerhardt Soeiro de Souza, Danielle Soares Bio, Vasco Videira Dias, Carolina Martins do Prado, Rodolfo Nunes Campos, Luis Felipe de Oliveira Costa, Doris Hupfeld Moreno, Elida Benquique Ojopi, Wagner Farid Gattaz, Ricardo Alberto Moreno
  [show abstract] [hide abstract]
  ABSTRACT: Apolipoprotein E (APOE) has been extensively studied as a risk factor for sporadic and late onset Alzheimer's Disease (AD). APOE allele (∗)3, the most frequent variant, is not associated to cognitive dysfunction (CD) or to increased AD risk. Differently, the (∗)4 allele is a well-established risk factor for CD, while the (∗)2 allele is associated with survival and longevity. CD is an important feature of Bipolar Disorder (BD) and recent data suggest that CD may be one of its endophenotypes, although controversial results exist. The aim of this research is to study the association of APOE genotype (APOE) and neurocognitive function in a sample of drug free young BD-type I patients. Sample consisted of 25 symptomatic BD (type I) patients (age 18-35 years old). They were submitted to an extensive neuropsychological evaluation and genotyped for APOE. Subjects with allele (∗)2 presented better cognitive performance. The presence of allele (∗)4 was associated with worse performance in a few executive tasks. APOE (∗)3(∗)3 was associated with overall severe dysfunction on cognitive performance. In young individuals with nontreated BD-type I, APOE may predict cognitive performance. Further and larger studies on APOE and cognition in BD are required to clarify whether APOE is a BD cognitive endophenotype.
  CNS Neuroscience & Therapeutics 10/2010; 16(5):316-21. · 4.44 Impact Factor